Background: Renal artery stenosis is among the most common curable causes of hypertension. The definitive diagnosis is made by renal angiography, an invasive and costly procedure. The prevalence of renal artery stenosis is less than 1% in non-selected hypertensive patients but is higher when hypertension is resistant to drugs. Objective: To study the usefulness of standardised twodrug regimens for identifying drug-resistant hypertension as a predictor of renal artery stenosis. Design and setting: Prospective cohort study carried out in 26 hospitals in The Netherlands. Patients: Patients had been referred for analysis of possible secondary hypertension or because hypertension was difficult to treat. Patients р40 years of age were assigned to either amlodipine 10 mg or enalapril 20 mg, and patients Ͼ40 years to either amlodipine 10 mg combined with atenolol 50 mg or to enalapril 20 mg combined with hydrochlorothiazide 25 mg. Renal angiography was performed: (1) if hypertension was drug-resistant, ie if diastolic pressure remained у95 mm Hg at three visits 1-3 weeks apart or an extra drug
Introduction
Renal artery stenosis is among the most common curable causes of hypertension, but its prevalence in non-selected patient populations is less than 1%. 1 The definitive diagnosis is made by renal angiography, an invasive procedure that is costly and not without risk. The question of how to select hyper-tensive subjects for angiography is therefore of considerable interest.
While the diagnosis of renal artery stenosis as an anatomical lesion is not without difficulties, the assessment of its functional significance is even more problematic. The effects of captopril or other angiotensin-converting enzyme (ACE) inhibitors on the renal scintigram, and measurements of renal vein renin have been used to predict angioplastic outcome. The predictive power of these tests is at best dubious, [2] [3] [4] [5] [6] [7] and renal vein renin sampling is a complex procedure. Rather than pursuing ever more sophisticated diagnostic procedures in an effort to find as many cases as possible, a better strategy could be to restrict diagnostic work-up to patients in whom hypertension is difficult to control by medication. The prevalence of renal artery stenosis is relatively high in such patients, [8] [9] [10] [11] and they are also the patients who may benefit most from angioplasty. There is, however, no uniform definition of so-called drug-resistant hypertension, because of the wide variety of antihypertensive drugs and drug regimens.
Renal artery stenosis is often associated with some degree of renin-angiotensin system hyperactivity, and ACE inhibitor treatment has been reported to be particularly effective in lowering blood pressure in patients with increased renin. 12 Persistent hypertension despite ACE inhibitor treatment, may therefore argue against the presence of renal artery stenosis. On the other hand, in some patients with renal artery stenosis renal function is highly angiotensin II-dependent, 13, 14 so that the occurrence of renal function impairment during ACE inhibitor treatment may help to identify these patients.
The objective of our study is to investigate the usefulness of standardised drug regimens for the identification of drug-resistant hypertension as a predictor of renal artery stenosis; a regimen consisting of amlodipine and atenolol was compared with a regimen consisting of enalapril and hydrochlorothiazide, both regimens being frequently used in first-line antihypertensive therapy. This report is part of the Dutch Renal Artery Stenosis Intervention Cooperative (DRASTIC) study.
Patients and methods
The DRASTIC study is a prospective study on renovascular hypertension, conducted at 26 clinical centres in The Netherlands. The aims were: (1) to design a strategy for selecting hypertensive patients for further diagnostic work-up and to optimize this work-up, and (2) to compare the effects of percutaneous transluminal renal angioplasty on blood pressure and renal function with the effects of drug treatment. 15 The present paper focuses on the question of how to select patients for diagnostic workup. The protocol for this study was approved by the ethics committees of the participating hospitals. All patients gave written informed consent.
Patient selection
The study was carried out in hypertensive patients of 18-75 years of age, who had been referred to the participating centres from January 1993 to September 1996. Reasons for referral were unsatisfactory blood pressure control or an adverse drug effect during the course of antihypertensive treatment, or analysis of possible secondary hypertension. Exclusion criteria were: suspected secondary hypertension other than renovascular disease, unstable coronary artery disease, heart failure, renal failure (serum creatinine у200 mol/L, у2.26 mg/dL), and inadequate contraception. Secondary hypertension other than renovascular disease was specified as abnormal urinalysis, signs of obstructive uropathy or renal scarring, symptoms or signs of pheochromocytoma or Cushing syndrome, or hypokalaemia associated with low plasma renin.
Standardised drug regimens
At intake, a record was made of the antihypertensive drugs the patient had been using. This medication was discontinued and the patient was assigned to one of the standardised drug regimens, which consisted of the calcium antagonist amlodipine (Am), the ACE inhibitor enalapril (En), the beta-blocker atenolol (At) and the diuretic hydrochlorothiazide (Th) in various combinations (Table 1 ). Patients р40 years were randomly assigned to either Am or En treatment, while patients Ͼ40 years were assigned to either Am+At or En+Th.
Patients who could not be treated with Am(+At) because of previous adverse reactions or (relative) contra-indications were treated with the En(+Th) regimen and vice versa. Patients who could not be treated with either Am or En received the At(+Th) regimen. Relative contra-indications were serum creatinine Ͼ120 mol/L (Ͼ1.36 mg/dL) in the case of enalapril and hydrochlorothiazide, chronic obstructive pulmonary disease or intermittent claudication in the case of atenolol, and diabetes mellitus in the case of atenolol and hydrochlorothiazide. Relative indications for the use of atenolol were angina pectoris or palpitations. When adverse reactions occurred during one of the standardised medication protocols, the patient switched to the other protocol. Drugs other than amlodipine, enalapril, atenolol or hydrochlorothiazide were used in patients who could not be assigned to any of the standardised regimens because of multiple adverse reactions or because their hypertension was considered too severe to be treated with only two drugs.
Follow-up and renal angiography
After intake, patients were seen at three consecutive visits, 1-3 weeks apart. Blood pressure was measured by standard sphygmomanometry, with the patient in the sitting position after 5 min of rest. 16 Measurements were made in triplicate and the results were averaged. During treatment with En(+Th), serum creatinine was monitored.
Patients who remained hypertensive, ie diastolic blood pressure у95 mm Hg during all three followup visits while on standardised medication, as well as patients requiring the addition of an extra drug during follow-up, were identified as having drugresistant hypertension ( Figure 1 ). Patients who could not be assigned to any of the standardised regimens and who required more than two drugs (or more than one drug when р40 years), were also considered to have drug-resistant hypertension. All patients with drug-resistant hypertension were Atenolol 100 mg once daily 1.33 Atenolol 100 mg once daily 2.33 + Hydrochlorothiazide 25 mg once daily *Total number of defined daily doses (DDD; the DDD is the assumed average maintenance dose per day for a drug used on its main indication in adults). requested to undergo renal angiography. Angiography was also performed in the patients who showed a у20 mol/L (у0.23 mg/dL) rise in serum creatinine during treatment with an ACE inhibitor, irrespective of their blood pressure response.
Angiography was carried out intra-arterially, using the digital subtraction technique. Radiologists from the participating centres were advised to make antero-posterior and antero-oblique (15-30 degrees) images; selective angiography was not routinely performed. The interpretation of the angiograms was carried out by the radiologist who had performed the investigation. Renal artery stenosis was defined as a reduction of the arterial lumen diameter by 50% or more.
Statistical analysis
Comparisons were made by the Student's t-test or the Wilcoxon rank sum test. For comparing the proportions of patients between groups, the chi-square test was used. All calculations of P values were twotailed. The patients who could not be randomly
Journal of Human Hypertension assigned to the standardised drug regimens, were analysed separately from the randomised patients, because the prevalence of drug-resistant hypertension is likely to be related to some of the reasons for non-randomisation.
Results

Assignment to standardised drug regimens
Enrolled in the study were 1205 patients. In 72 of them, a scintigraphic and/or angiographic diagnosis of renal artery stenosis had been made before assignment to standardised drug treatment. These patients were therefore excluded. The remaining 1133 patients (51.2 ± 12.4 yr, mean ± s.d.) were using an average of 1.4 ± 1.1 antihypertensive drugs at entry, in a dose corresponding with 2.0 ± 1.9 defined daily doses (DDDs; one DDD is the assumed average maintenance dose per day for a drug used on its main indication in adults). 17 Blood pressure at entry was 179 ± 26 mm Hg systolic and 109 ± 12 mm Hg diastolic. Serum creatinine was 86 (40-199) mol/L (median, range). The large majority of patients was assigned to either Am(+At) or En(+Th), three-quarters of them by randomisation (Figure 2 ). The reasons for non-randomisation are given in Table 2 . Of the 499 patients with complete follow-up who started with Am(+At), 375 patients used only Am(+At) for the full period of follow-up, 17 received an additional drug, and 107 were switched to a different regimen. Of the 523 patients with complete follow-up who started with En(+Th), 359 patients remained on this regimen, 21 received an additional drug, and 143 were switched to a different regimen.
Follow-up
Complete blood pressure data were available in 1106 patients. Although these patients were referred to the participating centres because of difficult-totreat hypertension, a large proportion became normotensive during follow-up while on the standardised treatment regimens with one or two drugs (Table 3) . Drug-resistant hypertension, as defined by the criteria of the present study, was demonstrated in 455 patients (41%). Of these patients, 92 (20.2%) were р40 years. Blood pressure at entry was higher among drug-resistant patients, and they used more medication (Table 3 ). In the drug-resistant group, blood pressure during follow-up was 170 ± 22 mm Hg systolic and 105 ± 9 mm Hg diastolic (average of the three follow-up visits) while on 3.2 ± 1.1 DDDs of antihypertensive drugs. Of the patients with complete follow-up, 43 of the 523 starting on ACE inhibitor (8%) showed a rise in Figure 2 Numbers of patients assigned to the standardised drug regimens. serum creatinine by у20 mol/L (у0.23 mg/dL). Creatinine at entry was higher in these patients than in those with stable creatinine levels (98, 59-199 mol/L vs 83, 40-197 mol/L [1.11, 0.67-2.25 mg/dL vs 0.94, 0.45-2.23 mg/dL], median and range, P = 0.002). Table 4 gives the prevalence of drug-resistant hypertension and the incidence of renal function impairment after ACE inhibitor treatment in the groups randomly assigned to Am(+At) or En(+Th) and in the groups not randomly assigned to these and other regimens. In the randomised patients, a larger proportion remained hypertensive during En(+Th) treatment than during Am(+At) treatment. The prevalence of drug-resistant hypertension was higher in the combined non-randomised groups than in the combined randomised groups (51 vs 37%, P Ͻ 0.001). The non-randomised groups also showed a higher incidence of renal function impairment after ACE inhibitor treatment (7 vs 2%, P Ͻ 0.001).
Renal angiography
Renal angiography was performed in 478 patients. The overall prevalence of renal artery stenosis was 22%. The stenosis was caused by atherosclerosis in 87 patients (81%) and by fibromuscular dysplasia in 17 (16%); distinction between these two causes was unclear in three patients. Fibromuscular dysplasia was observed in 75% of stenoses in patients р40 years, and in 11% in patients Ͼ40 years (P Ͻ 0.001). Complications of angiography were groin haema- toma necessitating blood transfusion (n = 5), vasovagal syncope (n = 2), and occlusion of the femoral artery, which had to be treated by surgical thrombectomy (n = 1). Table 4 shows the prevalence of renal artery stenosis in the patients who had drug-resistant hypertension or experienced ACE inhibitor-related renal function impairment in the different drug treatment groups. The prevalence of renal artery stenosis among the patients who underwent angiography was higher in the combined non-randomised groups than in the combined randomised groups (35 vs 15%, P Ͻ 0.001). In the randomised patients, the overall prevalence of renal artery stenosis was not different between the Am(+At) and En(+Th) groups (17 vs 13%, P = 0.41). The prevalence among patients р40 years was lower than among patients Ͼ40 years (10 vs 25%, P = 0.002). Bilateral stenosis was present in 20 patients (23%) with renal artery stenosis in the drug-resistant group and in seven (39%) in the renal function impairment group (P = 0.15). The prevalence of risk factors for renal artery stenosis in the different medication groups is given in Table 5 . Older age, vascular occlusive disease, smoking history and elevated serum creatinine were more common in the non-randomised patients.
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Discussion
Renovascular hypertension is defined as hypertension caused by renal artery stenosis. Restoration of blood pressure after repair of the stenosis is therefore the diagnostic proof. This, however, is a diagnosis a posteriori and therefore of little practical value. Moreover, hypertension may persist after angioplasty, due to technical failure of the procedure or restenosis. It is also possible that the patient has entered the advanced stage of hypertension, which corresponds with the irreversible phase of Goldblatt hypertension in animals. 18 The present paper describes a prospective cohort study and addresses the question of how to select patients for diagnostic work-up for renovascular hypertension. *P = 0.006 for difference with Am(+At) regimen. †These patients were switched to the En(+Th) regimen because of an adverse reaction to the Am(+At) regimen. In the clinical context, the demonstration of renal artery stenosis is a key step in the diagnosis of renovascular hypertension. Most clinicians agree that diagnostic work-up, including renal angiography, is warranted in patients who do not respond satisfactorily to so-called triple therapy. 9 On the other hand, few clinicians will advise adult patients, even those under 40 years, to undergo angiography when blood pressure can be readily controlled with one drug. Our study was primarily aimed at patients who belong to the intermediate category, ie patients Ͼ40 years who remain hypertensive despite treatment with two drugs, and patients р40 years who remain hypertensive while on treatment with one drug. The choice of 40 years of age as the point where a different strategy may apply, is arbitrary. It arises from the intention not to miss fibromuscular dysplasia, which has a higher prevalence at younger age and can be treated successfully by balloon angioplasty with less risk of restenosis than in atherosclerotic disease. 19 The treatment regimens in this study are frequently used in The Netherlands. The drugs in these regimens belong to classes that are also used in other countries, although individual drugs and dosages may differ between countries. It is probably justifiable to extrapolate our results to other drug regimens, provided that these regimens are of comparable antihypertensive efficacy. The number of DDDs can be used as a measure of comparison (Table 1) .
Selection criteria for renal angiography in our study were drug-resistant hypertension or ACE inhibition-related renal function impairment. We found that persistent hypertension was more common in the patients randomised to the En(+Th) protocol than in the patients randomised to the Am(+At) protocol, which we explain by a somewhat stronger antihypertensive effect of Am(+At) compared to En(+Th). However, the absolute number of patients with renal artery stenosis in both groups did not differ significantly, so that more angiograms were necessary in the En(+Th) group to diagnose the same number of stenoses as in the Am(+At) group. In the patients randomised to En(+Th), deterioration of renal function following administration of the ACE inhibitor was rare, so that this effect had little diagnostic impact, despite the high prevalence of renal artery stenosis in patients showing this phenomenon. Deterioration of renal function after ACE inhibition was not an exclusive finding for patients with bilateral disease; in fact, more than half of the patients with this finding had unilateral renal artery stenosis. Probably concurrent arteriolosclerosis is responsible for the decrease in glomerular filtration after eliminating the effect of angiotensin II.
We did not investigate the prevalence of renal artery stenosis in the patients who showed adequate blood pressure control after medical treatment. Literature data suggest that in these patients renal artery stenosis is rare, because refractory hypertension is a powerful predictor of renal artery stenosis. 10, 20 Moreover, identification of renal artery stenosis when the hypertension can be readily controlled by drugs is of less practical importance, because such patients have a smaller chance to develop target organ damage. Since blood pressure in patients with renal artery stenosis is said to be particularly responsive to ACE inhibition, one could argue that we missed more cases in the group randomised for En(+Th) than in the group randomised for Am(+At). This seems unlikely, because our detection rate in the En(+Th) group was not lower than in the Am(+At) group as stated above, while in both groups 96% of the patients eligible for angiography had indeed been subjected to this procedure.
The non-randomised patients had a higher prevalence of renal artery stenosis than the randomised patients. This is to be expected, given the fact that the reasons for non-randomisation included the presence of angina pectoris or claudication, which are symptoms of atherosclerotic disease. Elevated serum creatinine was also a reason for nonrandomisation, and this can be a sign of atherosclerotic disease of the renal arteries or smaller renal vessels.
We conclude that the use of standardised twodrug regimens to identify drug-resistant hypertension, is sufficient to increase the average a priori chance of renal artery stenosis to 20% or more. In this respect, the combination amlodipine (10 mg) and atenolol (50 mg) appears at least as effective as the combination enalapril (20 mg) and hydrochlorothiazide (25 mg). ACE inhibition-related renal function impairment is too rare to make the Journal of Human Hypertension enalapril/thiazide combination a better predictor of renal artery stenosis than the amlodipine/atenolol combination. The use of these two-drug combinations is a rational first step in the diagnostic workup for renovascular hypertension. By taking into consideration some other well known clinical characteristics, 21 the risk estimation can be narrowed down to the individual patient.
